breast cancer

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two essential changes for Puma Biotechnology Inc (NASDAQ: PBYI) Nerlynx (neratinib). The first update added...

Merus NV (NASDAQ: MRUS) has presented updated data on zenocutuzumab (Zeno) combined with trastuzumab and vinorelbine in HER2 positive/amplified (HER2+) metastatic breast cancer who had progressed on anti-HER2 antibody-drug conjugates. The reported data are from the completed phase 2...

Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).  MARIO-3 Phase 2 trial is evaluating eganelisib in combination with Roche Holdings AG's (OTC: RHHBY)...

Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).  ARV-471...

Context Therapeutics Inc (NASDAQ: CNTX) posted data from the window-of-opportunity trial of onapristone extended-release (ONA-XR) in postmenopausal patients with progesterone receptor-positive (PR+) early breast cancer. The data were presented at San Antonio Breast Cancer...

Ambrx Biopharma Inc's (NYSE: AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented favorable safety and efficacy data from its ongoing ACE-Breast-01 Phase 1 study of ARX788 at the San Antonio Breast Cancer Symposium (SABCS). ARX788 demonstrated treatment effect...

Seagen Inc (NASDAQ: SGEN) has revealed new data from exploratory analyses from the HER2CLIMB trial of Tukysa (tucatinib) combined with trastuzumab & capecitabine in HER2-positive metastatic breast cancer with stable or active brain metastases. The data were featured at the 2021...

Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer and proven overall survival (OS) benefit across patient subgroups. The findings will be presented as a late-breaking oral...

The Menarini Group and Radius Health Inc (NASDAQ: RDUS) have provided details on the elacestrant data from the EMERALD Phase 3 trial presented at the San Antonio Breast Cancer Symposium. As previously announced, the study met its two primary endpoints: progression-...

Olema Pharmaceuticals Inc (NASDAQ: OLMA) had been preparing to present the first clinical data from its lead program in development for metastatic breast cancer at a conference next week. But its poster supposedly leaked online on Monday.  In response, Olema issued a statement...

The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) for breast cancer. The application for Lynparza covers the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high...

Health Canada has conditionally approved Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) for a form of breast cancer. The approval covers adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1...

The European Commission has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan) as monotherapy for triple-negative breast cancer (TNBC). The approval for the antibody-drug conjugate covers adult patients with unresectable or metastatic TNBC who have...

Athenex Inc's (NASDAQ: ATNX) abstract for subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral Paclitaxel) for metastatic breast cancer has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium. The abstract and poster provide data...

Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-induced diarrhea (CID). The trial included HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab,...